-
Befotertinib Mesylate Capsules Approved for Marketing
2023-05-31
Recently, the Class I innovative product Befotertinib Mesylate Capsules (Chinese trade name: 赛美纳) of Betta Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Alfosbuvir Tablets Approved for Marketing
2023-05-17
Recently, the Class-1 innovative drug Alfosbuvir Tablets (Chinese trade name:圣诺迪) of Nanjing Sanhome Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Zuberitamab Injection Approved for Marketing
2023-05-17
Recently, the Zuberitamab injection (Chinese trade name: 安瑞昔) of Zhejiang BioRay Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of CD20 positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) for adult patients, and should be combined with standardized CHOP therapies (cyclophosphamide, doxorubicin, vincristine, prednisone).
-
Leritrelvir Tablets for treating COVID-19 infection approved with conditions for marketing
2023-03-23
Recently, the class 1 innovative drug Leritrelvir Tablets (Chinese trade name: 乐睿灵) of Guangdong Raynovent Biotech Co., Ltd is approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Gumarontinib tablets approved with conditions for marketing
2023-03-08
Recently, the Class I innovative product Gumarontinib tablets of Haihe Biopharma Co., Ltd. is approved with conditions by China NMPA.
-
Keverprazan Hydrochloride Tablets approved for marketing
2023-02-01
Recently, the class 1 innovative drug Keverprazan Hydrochloride Tablets of Jiangsu Carephar Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
